Holen Sie sich die Stockscreener-App
325.11
2.17%
6.89
Vorhandelsmarkt:
326.10
0.99
+0.30%
Schlusskurs vom Vortag:
$318.22
Offen:
$321.78
24-Stunden-Volumen:
338.90K
Relative Volume:
0.55
Marktkapitalisierung:
$9.05B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-35.45
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-6.46%
1M Leistung:
+7.18%
6M Leistung:
+605.38%
1J Leistung:
+797.85%
1-Tages-Spanne:
$319.28
$332.57
1-Wochen-Bereich:
$314.64
$354.87
52-Wochen-Spanne:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
325.11 | 8.86B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A Look At Praxis Precision Medicines (PRAX) Valuation After Wider Full Year And Q4 Net Loss - simplywall.st
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Praxis gives 2,931 stock units to 14 new employees - Stock Titan
PRAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures - Citeline News & Insights
Why (PRAX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
GSA Capital Partners LLP Trims Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Powerhouse with 76% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Praxis (PRAX) Wider Losses, Fresh NDAs And Multi‑Year Cash Runway - simplywall.st
PRAX Should I Buy - Intellectia AI
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Wolfe Research - MarketBeat
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Assessing Praxis Precision Medicines (PRAX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Wolfe Research initiates Praxis stock with outperform rating - Investing.com
Wolfe Research initiates Praxis stock with outperform rating By Investing.com - Investing.com India
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Wolfe Research Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum - Yahoo Finance
3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC - MarketBeat
Praxis NDAs And FDA Designations Put Focus On Valuation Upside - Yahoo! Finance Canada
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines - Intellectia AI
Praxis Precision Medicines Maps Aggressive Path to Market - TipRanks
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - Yahoo Finance
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - The Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress - AOL.com
Praxis Medicines Q4 2025 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Analyst Upgrade - Defense World
PRAX Stock: Wells Fargo Raises Price Target to $305 | PRAX Stock News - GuruFocus
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Asianet Newsable
Praxis Precision Medicines stock reaches 52-week high at 337.01 USD - Investing.com
Baird Raises Price Target for PRAX to $433, Maintains Outperform Rating | PRAX Stock News - GuruFocus
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
Praxis Precision Medicines Stock Surges on FDA Momentum - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Truist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Wedbush Raises Price Target on Praxis Precision Medicines to $130 From $95, Keeps Underperform Rating - marketscreener.com
Truist Boosts Price Target on Praxis Precision Medicines to $700 From $500, Keeps Buy Rating - marketscreener.com
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $412 From $357, Keeps Buy Rating - marketscreener.com
Wedbush Raises Price Target for PRAX to $130 Despite 'Underperfo - GuruFocus
Wedbush Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential - TipRanks
Earnings call transcript: Praxis Precision Q4 2025 misses EPS forecast By Investing.com - Investing.com Canada
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call High - GuruFocus
Truist reiterates Praxis Precision Medicines stock rating on pricing potential By Investing.com - Investing.com Nigeria
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):